Access

Letter

Nature 436, 1025-1029 (18 August 2005) | doi:10.1038/nature03844; Received 23 March 2005; Accepted 23 May 2005; Published online 17 July 2005

Open Innovation Challenges

naturejobs

Dystrophic heart failure blocked by membrane sealant poloxamer

Soichiro Yasuda1,3, DeWayne Townsend1,3, Daniel E. Michele1,2, Elizabeth G. Favre1, Sharlene M. Day2 & Joseph M. Metzger1,2

  1. Departments of Molecular and Integrative Physiology and
  2. Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0622, USA
  3. *These authors contributed equally to this work

Correspondence to: Joseph M. Metzger1,2 Correspondence and requests for materials should be addressed to J.M. (Email: metzgerj@umich.edu).

Top

Dystrophin deficiency causes Duchenne muscular dystrophy (DMD) in humans, an inherited and progressive disease of striated muscle deterioration that frequently involves pronounced cardiomyopathy1. Heart failure is the second leading cause of fatalities in DMD1, 2. Progress towards defining the molecular basis of disease in DMD has mostly come from studies on skeletal muscle, with comparatively little attention directed to cardiac muscle. The pathophysiological mechanisms involved in cardiac myocytes may differ significantly from skeletal myofibres; this is underscored by the presence of significant cardiac disease in patients with truncated or reduced levels of dystrophin but without skeletal muscle disease3. Here we show that intact, isolated dystrophin-deficient cardiac myocytes have reduced compliance and increased susceptibility to stretch-mediated calcium overload, leading to cell contracture and death, and that application of the membrane sealant poloxamer 188 corrects these defects in vitro. In vivo administration of poloxamer 188 to dystrophic mice instantly improved ventricular geometry and blocked the development of acute cardiac failure during a dobutamine-mediated stress protocol. Once issues relating to optimal dosing and long-term effects of poloxamer 188 in humans have been resolved, chemical-based membrane sealants could represent a new therapeutic approach for preventing or reversing the progression of cardiomyopathy and heart failure in muscular dystrophy.

  1. Departments of Molecular and Integrative Physiology and
  2. Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0622, USA
  3. *These authors contributed equally to this work

Correspondence to: Joseph M. Metzger1,2 Correspondence and requests for materials should be addressed to J.M. (Email: metzgerj@umich.edu).

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Utrophin muscles in on the action

Nature Medicine News and Views (01 Jan 1997)

Muscle transfection made easy

Nature News and Views (29 Aug 1991)

See all 8 matches for News And Views